Improving access to SLE therapies in low and middle-income countries

Keyphrases

• Access to Care 50%
• Access to Therapy 50%
• Cost-effectiveness Analysis 50%
• Disease Burden 50%
• Expanded Access 100%
• High Cost 50%
• Lack of Access 50%
• Low-middle Income Countries 100%
• Lupus 50%
• Medical Society 50%
• Multiple Stakeholders 50%
• Pharmaceutical Industry 50%
• Regional Strategy 50%
• Supranational Organizations 50%

Medicine and Dentistry

• Cost-Effectiveness Analysis 25%
• Disease Burden 25%
• Drug Therapy 25%
• Health Care Cost 50%
• Low and Middle Income Countries 100%
• Lupus Erythematosus 25%
• Population 25%
• Systemic Lupus Erythematosus 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 25%
• Systemic Lupus Erythematosus 100%